ATRS Antares Pharma Inc.

Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Antares Pharma, Inc. (ATRS) and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Antares Pharma, Inc. (NASDAQ:ATRS) securities between December 21, 2016 and October 12, 2017 (the “Class Period”). Investors have until December 22, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Antares develops pharmaceutical delivery systems, distributes its needle-free injector systems in various countries, and conducts research and development with transdermal gel products. On December 21, 2016, Antares announced its submission of a New Drug Application (“NDA”) for Xyosted to the U.S. Food and Drug Administration (“FDA”). Antares’s product Xyosted has been among its lead product candidates throughout the Class Period.

On October 11, 2017, the Company received a letter from the FDA, stating that the agency had “identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments” for Xyosted.

Following this news, Antares shares fell $1.41 per share, or over 37%, to close at $2.32 per share on October 13, 2017.

On October 20, 2017, Antares announced receipt of a Complete Response Letter from the FDA regarding Xyosted’s NDA. The Company stated that the FDA could not approve the NDA in its present form due to concerns that Xyosted “could cause a clinically meaningful increase in blood pressure” and also noted the FDA’s concerns “regarding the occurrence of depression and suicidality.”

If you purchased or otherwise acquired Antares securities during the Class Period and suffered a loss, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Antares lawsuit, please go to www.bespc.com/atrs. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

EN
11/12/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Antares Pharma Inc.

 PRESS RELEASE

Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment fo...

Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy Commercial launch expected in 2Q 2022 EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males. Ro...

 PRESS RELEASE

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and...

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record reven...

 PRESS RELEASE

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conferen...

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42nd Annual Healthcare Conference being held on March 7-9, 2022. Details of the presentation are as follows: Event:  Cowen 42nd Annual Healthcare ConferenceFormat:  Fireside Chat and 1x1 MeetingsPresentation Date: Tuesday, March ...

 PRESS RELEASE

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial A...

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The co...

 PRESS RELEASE

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO...

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO® PDUFA target action date set for March 28, 2022 EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch